Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026GlobeNewsWire • 10/19/26
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewsWire • 09/03/26
Altimmune's Phase III MASH Study Puts 2029 Data in Investor FocusZacks Investment Research • 08/19/26
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?Zacks Investment Research • 08/19/26
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in FocusZacks Investment Research • 08/13/26
Altimmune Announces Second Quarter 2026 Financial Results and Business UpdateGlobeNewsWire • 08/12/26
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026GlobeNewsWire • 08/05/26
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASHGlobeNewsWire • 08/03/26
Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder TranscriptSeeking Alpha • 07/28/26
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use DisorderGlobeNewsWire • 07/28/26
Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - UpgradeSeeking Alpha • 07/07/26
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerZacks Investment Research • 06/26/26
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/10/26